Craft
  • Home
  •  / Repare Therapeutics
Repare Therapeutics

Repare Therapeutics

Revenue

$7.6 M

FY, 2021

Market Capitalization

$716.2 M

2022-11-22

Repare Therapeutics Summary

Company summary

Overview
Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare Therapeutics's platform combines CRISPR‐enabled gene-editing target discovery technology with high‐resolution protein crystallography, computational biology, medicinal chemistry, and clinical informatics.
Type
Public
Status
Active
Founded
2016
HQ
Montréal, CA | view all locations
Website
http://www.reparerx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Lloyd M. Segal

    Lloyd M. Segal, President & CEO and Director

  • Thomas Civik, Chairman of the Board

    • Steve Forte

      Steve Forte, EVP, Chief Financial Officer

    • Maria Koehler

      Maria Koehler, EVP & Chief Medical Officer

    LocationsView all

    2 locations detected

    • Montréal, QC HQ

      Canada

      7210 Rue Frederick Banting #100, Saint-Laurent

    • Cambridge, MA

      United States

      One Broadway, 1 Broadway 15th Floor

    Repare Therapeutics Financials

    Summary financials

    Revenue (Q2, 2022)
    $C679.0K
    Gross profit (Q2, 2022)
    $C679.0K
    Net income (Q2, 2022)
    ($C38.1M)
    Cash (Q2, 2022)
    $C275.8M
    EBIT (Q2, 2022)
    ($C38.7M)
    Enterprise value
    $440.3M

    Footer menu